Dr. Reddy’s names Akhil Ravi to Management Council

Akhil Ravi led the implementation of Aurigene.ai, which supports approximately 30% of the drug discovery services business.

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories (RDY) appointed Akhil Ravi as Head API and Services and Senior Management Personnel and inducted him into the Management Council, effective November 13, 2026. He will continue to be responsible for operations of Aurigene Pharmaceutical Services Ltd., a wholly owned subsidiary. Ravi is a related party as the son-in-law of G V Prasad, Co-Chairman and Managing Director. His profile describes nearly 19 years of experience and states that Aurigene.ai, an AI-enabled integrated drug discovery workflow whose implementation he led, supports approximately 30% of the drug discovery services business.

Key Figures

Appointment effective date: November 13, 2026 Experience: Nearly 19 years Drug discovery services business supported by Aurigene.ai: Approximately 30%

3 metrics

Appointment effective date November 13, 2026 Akhil Ravi’s appointment and Management Council induction

Experience Nearly 19 years Akhil Ravi’s experience, as described in his profile

Drug discovery services business supported by Aurigene.ai Approximately 30% As stated in Akhil Ravi’s profile

Key Terms

CRDMO, CDMO, Aurigene.ai

3 terms

CRDMO technical

"into a rapidly scaling CRDMO"

A CRDMO is a third-party firm that combines research, development and manufacturing services for drugs or medical products, handling tasks from lab testing and product design through to large-scale production. For investors, a CRDMO is important because it lets healthcare companies scale and reduce upfront costs and technical risk—like hiring a full-service contractor to design and build a house instead of doing each job yourself—which can affect a firm’s timelines, expenses and potential returns.

CDMO technical

"across the CDMO business"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

Aurigene.ai technical

"implementation of Aurigene.ai"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Akhil Ravi’s appointment at RDY take effect?

Akhil Ravi’s appointment as Head API and Services and Senior Management Personnel, with induction to the Management Council, is effective November 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/23/2026 - 02:16 PM EDT Accepted by SEC EDGAR 10/23/2026 - 02:15 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

October 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨ No  x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated October 23, 2026

 2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: October 23, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

 3

Exhibit 99.1

  Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India   CIN: L85195TG1984PLC004507   Tel:        + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

October 23, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Senior Management Personnel

Pursuant to the recommendation of the Nomination, Governance and Compensation Committee and Audit Committee, the Board of Directors of the Company, at their meeting held today, approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel of the Company, and his induction as a Member of the Management Council of the Company, effective November 13, 2026. Mr. Akhil Ravi will continue to be responsible for the operations of Aurigene Pharmaceutical Services Ltd. a wholly owned subsidiary of the Company. Mr. Akhil Ravi is a related party to the Company, being the son-in-law of Mr. G V Prasad, Co-Chairman and Managing Director.

The updated list of the Company's Senior Management Personnel, reflecting the above appointment, is enclosed as Annexure.

The disclosure required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure A.

The Board Meeting commenced at 3:00 p.m. IST and concluded at 4:38 p.m. IST.

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

  

 K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Encl: as above

 

Details of Mr. Akhil Ravi

Sl.no.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	Effective from November 13, 2026 Appointed as Head API and Services and Senior Management Personnel of the Company, and inducted as a Member of the Management Council of the Company
3.	Brief profile (in case of appointment)	As mentioned below
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable.

Brief Profile of Mr. Akhil Ravi

 

Akhil Ravi brings nearly 19 years of experience spanning strategy, commercial leadership, business transformation and general management. Since joining Dr. Reddy's Laboratories in 2018, he has held leadership roles across strategy, commercial operations and business leadership, and currently serves as CEO of Aurigene Pharmaceutical Services Ltd. (APSL), a wholly owned subsidiary of Dr. Reddy’s Laboratories. In this role, he has led APSL's evolution from a start-up-style business into a rapidly scaling CRDMO, driving significant growth, profitability and capability expansion.

Since joining Dr. Reddy’s, Akhil has led the transformation of APSL through a multi-year agenda focused on strengthening operating foundations, accelerating growth, improving profitability and enhancing customer service. Under his leadership, the business is on track and on growth trajectory. He has also driven a significant improvement in service levels across the CDMO business, strengthening both operational performance and customer confidence.

  

Akhil has been instrumental in advancing APSL's innovation and technology capabilities. He led the implementation of Aurigene.ai, an AI-enabled integrated drug discovery workflow that now supports approximately 30% of the drug discovery services business. He has also overseen the expansion of capabilities across drug discovery, antibodies, biologics, APIs and peptides, while laying the foundation for growth in the drug product CDMO business through strategic partnerships.

Before joining Dr. Reddy's, Akhil held sales and transformation roles at McKinsey & Company and ITC and also pursued entrepreneurial ventures focused on digital sports and health solutions.

Akhil has done Post-Graduate Programme in Management from Indian School of Business (ISB) and graduated in Bachelor of Technology, Chemical Engineering from Indian Institute of Technology (IIT), Bombay.

 

Annexure

List of revised Senior Management Personnel

Sl.No	Name of the SMP	Designation
1	Mr. Satish Reddy	Chairman and Whole-time Director
2	Mr. G V Prasad	Co-Chairman and Managing Director (KMP)
3	Mr. Erez Israeli	Chief Executive Officer (KMP)
4	Mr. M V Ramana	CEO Global Generics
5	Mr. Sanjay Sharma	Chief Operating Officer
6	Mr. M V Narasimham	Chief Financial Officer (KMP)
7	Mr. Deepak Sapra	Chief Executive Officer, API and Services
8	Mr. Krishna Venkatesh	Global Head of IPDO - Integrated Product Development Organization
9	Mr. Patrick Aghanian	Head - Consumer Health Organization
10	Mr. Phanimitra B	Chief Digital and Information Officer
11	Mr. Milan Kalawadia	Chief Executive Officer, North America
12	Mr. M S Madhu Sundar	Global Head of Quality and PV
13	Mr. Sandeep Khandelwal	Chief Executive Officer – Asia, Africa, Australia & CISUR
14	Dr. Sridevi Khambhampaty	Global Head of Biologics
15	Mr. Akhil Ravi	Head API and Services
16	Mr. K Randhir Singh	Company Secretary, Compliance Officer and Head-CSR (KMP)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 31.3 KB